Evidence map›Paper›PMID 25984272›Full record

ArticleClinical and translational medicine2014

Gene expression profiling of immunomagnetically separated cells directly from stabilized whole blood for multicenter clinical trials.

Martin Letzkus, Evert Luesink, Sandrine Starck-Schwertz, Marc Bigaud, Fareed Mirza, Nicole Hartmann, Bernhard Gerstmayer, Uwe Janssen, Andreas Scherer, Martin M Schumacher and 5 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Martin LetzkusBiomarker Development, Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Evert LuesinkBiomarker Development, Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Sandrine Starck-SchwertzBiomarker Development, Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Marc BigaudBiomarker Development, Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Fareed MirzaScientific Capability Development, Pharma-Development, Novartis Pharma AG, Basel, Switzerland.
Nicole HartmannBiomarker Development, Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Bernhard GerstmayerMiltenyi Biotec GmbH, Bergisch Gladbach, Germany.
Uwe JanssenMiltenyi Biotec GmbH, Bergisch Gladbach, Germany.
Andreas SchererSpheromics, Kontiolahti, Finland.
Martin M SchumacherBiomarker Development, Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Aurelie VerlesBiomarker Development, Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Alessandra VitalitiBiomarker Development, Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Nanguneri NirmalaBiomarker Development, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, USA.
Keith J JohnsonBiomarker Development, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, USA.
Frank StaedtlerBiomarker Development, Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Novartis Institutes for BioMedical ResearchNovartis (Switzerland) · CHMiltenyi Biotec (Germany) · DENovartis (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinically useful biomarkers for patient stratification and monitoring of disease progression and drug response are in big demand in drug development and for addressing potential safety concerns. Many diseases influence the frequency and phenotype of cells found in the peripheral blood and the transcriptome of blood cells. Changes in cell type composition influence whole blood gene expression analysis results and thus the discovery of true transcript level changes remains a challenge. We propose a robust and reproducible procedure, which includes whole transcriptome gene expression profiling of major subsets of immune cell cells directly sorted from whole blood.

methodsTarget cells were enriched using magnetic microbeads and an autoMACS® Pro Separator (Miltenyi Biotec). Flow cytometric analysis for purity was performed before and after magnetic cell sorting. Total RNA was hybridized on HGU133 Plus 2.0 expression microarrays (Affymetrix, USA). CEL files signal intensity values were condensed using RMA and a custom CDF file (EntrezGene-based).

resultsPositive selection by use of MACS® Technology coupled to transcriptomics was assessed for eight different peripheral blood cell types, CD14+ monocytes, CD3+, CD4+, or CD8+ T cells, CD15+ granulocytes, CD19+ B cells, CD56+ NK cells, and CD45+ pan leukocytes. RNA quality from enriched cells was above a RIN of eight. GeneChip analysis confirmed cell type specific transcriptome profiles. Storing whole blood collected in an EDTA Vacutainer® tube at 4°C followed by MACS does not activate sorted cells. Gene expression analysis supports cell enrichment measurements by MACS.

conclusionsThe proposed workflow generates reproducible cell-type specific transcriptome data which can be translated to clinical settings and used to identify clinically relevant gene expression biomarkers from whole blood samples. This procedure enables the integration of transcriptomics of relevant immune cell subsets sorted directly from whole blood in clinical trial protocols.

Indexed as

Cell sortingClinicalTranscriptomics

Identifiers

PMID25984272
PMCPMC4424390
OpenAlexW2159867343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.